Department of Pediatrics

Education

• BS, Massachusetts Institute of Technology, 2008
• MD, New York Medical College, 2015

Training

• Residency in Pediatrics, Washington University in St. Louis/St. Louis Children's Hospital, 2015 - 2018
• Fellowship in Pediatric Emergency Medicine, Medical College of Wisconsin, 2018 - 2021

Licensure and Board Certification

• 2015 - PresBasic Life Support
• 2015 - PresPediatric Advanced Life Support
• 2018 - 2021WI, Medical License
• 2018 - 2021WI, DEA
• 2018 - 2022Pediatric Fundamental Critical Care Support
• 2018 - PresAdvanced Trauma Life Support
• 2018 - PresAmerican Board of Pediatrics
• 2019 - PresImageSIM POCUS Training Course
• 2021 - PresMO, Medical License
• 2021 - PresMO, BNDD
• 2021 - PresMO, DEA

Honors and Awards

• Career Development Award, 29th Annual Wisconsin Emergency Medicine Forum, 2021

Recent Publications view all (10)

1. Park ER, Smith KB, Merker VL, Muzikansky A, Vranceanu AM, WANG DL, Plotkin SR. Examining perceived cancer risk among patients with neurofibromatosis type 1 J Neurooncol. 2015;122(1):127-133. doi:10.1007/s11060-014-1689-6  PMID:25559686 
2. Smith KB, WANG DL, Plotkin SR, Park ER. Appearance concerns among women with neurofibromatosis: examining sexual/bodily and social self-consciousness Psychooncology. 2013;22(12):2711-2719. doi:10.1002/pon.3350  PMID: 23873824 
3. Clark SW, Taylor J, WANG DL, Abramson JS, Batchelor TT. Plasmablastic lymphoma after standard-dose temozolomide for newly diagnosed glioblastoma Neurology. 2013;81(1):93-94. doi:10.1212/WNL.0b013e318297eea6  PMCID:PMC3770207  PMID:23685934 
4. WANG DL, Smith KB, Esparza S, Leigh FA, Muzikansky A, Park ER, Plotkin SR. Emotional functioning of patients with neurofibromatosis tumor suppressor syndrome Genet Med. 2012;14(12):977-982. doi:10.1038/gim.2012.85  PMCID:PMC3982605  PMID: 22878510 
5. Chi AS, Batchelor TT, Dias-Santagata D, Border D, Stiles CD, WANG DL, Curry WT, Wen PY, Ligon KL, Ellisen L, Louis DN, Iafrate AJ. Prospective high-throughput molecular profiling of human gliomas J Neurooncol. 2012;110(1):89-98. doi:10.1007/s11060-012-0938-9  PMCID:PMC3583376  PMID:22821383 
6. Quant EC, Nutt CL, WANG D, Batchelor TT. Targeting the epidermal growth factor pathway as therapy for glioblastoma Current Cancer Therapy Reviews. 2012;7(11):65-66. doi:10.2174/157339411794474146  
7. Chi AS, Batchelor TT, Kwak EL, Clark JW, WANG DL, Wilner KD, Louis DN, Iafrate AJ. Rapid radiographic and clinical improvement after treatment of a MET-amplified recurrent glioblastoma with a mesenchymal-epithelial transition inhibitor J Clin Oncol. 2011;30(3):30-33. doi:10.1200/JCO.2011.38.4586  PMID:22162573 
8. Eichler AF, Kahle KT, WANG DL, Joshi VA, Willers H, Engelman JA, Lynch TJ, Sequist LV. EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer Neuro Oncol. 2010;12(11):1193-1199. doi:10.1093/neuonc/noq076  PMCID:PMC3098020  PMID:20627894 
9. Gerstner ER, Yip S, WANG DL, Louis DN, Iafrate AJ, Batchelor TT. MGMT methylation is a prognostic biomarker in elderly patients with newly diagnosed glioblastoma Neurology. 2009;73(18):1509-1510. doi:10.1212/WNL.0b013e3181bf9907  PMCID:PMC2779003  PMID: 19884580 
10. Dietrich J, WANG D, Batchelor, TT. Cediranib – Profile of a novel anti-angiogenic agent in patients with glioblastoma Expert Opin Investig Drugs. 2009;10(18):1549-1557. doi:10.1517/13543780903183528  PMCID:PMC2761074  PMID:19671039